16-30 of 305
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
MinuteCE®HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
Barbara O'Brien, MD
Nadia Harbeck, MD, PhD
First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases
MinuteCE®First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases
Barbara O'Brien, MD
Nadia Harbeck, MD, PhD
Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC
MinuteCE®Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC
Benjamin Levy, MD
Melin Khandekar, MD, PhD
EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions
MinuteCE®EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions
Benjamin Levy, MD
Melin Khandekar, MD, PhD
Managing Brain Metastases Through Multidisciplinary Team Collaboration
MinuteCE®Managing Brain Metastases Through Multidisciplinary Team Collaboration
Benjamin Levy, MD
Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
CME/CERethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
Mukul Sharma, MD, MSc, FRCPC
Ashkan Shoamanesh, MD, MSc, FRCPC
- advertisement
Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents
CME/CEAdvances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents
Guy Young, MD
Annette von Drygalski, MD, PharmD, RMSK
Steven Pipe, MD
Robert Sidonio Jr, MD, MSc
Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
CME/CELiving With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
Cem Akin, MD, PhD
Precision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
CME/CEPrecision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
Harry Erba, MD, PhD
Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
CME/CENavigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
Mariana C. Castells, MD, PhD
Tsewang Tashi, MD
The Future of HNSCC: Aligning Teams, Transforming Care
CME/CEThe Future of HNSCC: Aligning Teams, Transforming Care
Ravindra Uppaluri, MD, PhD
Nancy Lee, MD, FASTRO
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
CME/CEChairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Benjamin Levy, MD
- advertisement
Targeting B7-H3 in ES-SCLC: Advancing Targeted Therapy Through Evidence-Based Innovation and Multidisciplinary Care
CME/CETargeting B7-H3 in ES-SCLC: Advancing Targeted Therapy Through Evidence-Based Innovation and Multidisciplinary Care
Taofeek K. Owonikoko, MD, PhD
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
CME/CEAdvancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
María-Victoria Mateos, MD, PhD
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
CME/CENavigating Treatment Sequencing After Frontline Treatment Failure in CLL
Jennifer R. Brown, MD, PhD
William Mencia, MD, FACEHP
